75 related articles for article (PubMed ID: 24072268)
21. Penetrance analysis of the PALB2 c.1592delT founder mutation.
Erkko H; Dowty JG; Nikkilä J; Syrjäkoski K; Mannermaa A; Pylkäs K; Southey MC; Holli K; Kallioniemi A; Jukkola-Vuorinen A; Kataja V; Kosma VM; Xia B; Livingston DM; Winqvist R; Hopper JL
Clin Cancer Res; 2008 Jul; 14(14):4667-71. PubMed ID: 18628482
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis.
Cybulski C; Kluźniak W; Huzarski T; Wokołorczyk D; Kashyap A; Jakubowska A; Szwiec M; Byrski T; Dębniak T; Górski B; Sopik V; Akbari MR; Sun P; Gronwald J; Narod SA; Lubiński J;
Lancet Oncol; 2015 Jun; 16(6):638-44. PubMed ID: 25959805
[TBL] [Abstract][Full Text] [Related]
23. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review.
Bonadona V; Dussart-Moser S; Voirin N; Sinilnikova OM; Mignotte H; Mathevet P; Brémond A; Treilleux I; Martin A; Romestaing P; Raudrant D; Rudigoz RC; Lenoir GM; Lasset C
Breast Cancer Res Treat; 2007 Jan; 101(2):233-45. PubMed ID: 17061047
[TBL] [Abstract][Full Text] [Related]
24. Germline 657del5 mutation in the NBS1 gene in patients with malignant melanoma of the skin.
Debniak T; Górski B; Cybulski C; Jakubowska A; Kurzawski G; Lener M; Mierzejewski M; Masojć B; Medrek K; Kładny J; Załuga E; Maleszka R; Chosia M; Lubiński J
Melanoma Res; 2003 Aug; 13(4):365-70. PubMed ID: 12883362
[TBL] [Abstract][Full Text] [Related]
25. A 10-year follow-up of triple-negative breast cancer patients in Taiwan.
Lin C; Chien SY; Kuo SJ; Chen LS; Chen ST; Lai HW; Chang TW; Chen DR
Jpn J Clin Oncol; 2012 Mar; 42(3):161-7. PubMed ID: 22287721
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer predisposing alleles in Poland.
Górski B; Cybulski C; Huzarski T; Byrski T; Gronwald J; Jakubowska A; Stawicka M; Gozdecka-Grodecka S; Szwiec M; Urbański K; Mituś J; Marczyk E; Dziuba J; Wandzel P; Surdyka D; Haus O; Janiszewska H; Debniak T; Tołoczko-Grabarek A; Medrek K; Masojć B; Mierzejewski M; Kowalska E; Narod SA; Lubiński J
Breast Cancer Res Treat; 2005 Jul; 92(1):19-24. PubMed ID: 15980987
[TBL] [Abstract][Full Text] [Related]
27. Is conservative surgery a good option for patients with "triple negative" breast cancer?
Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
[TBL] [Abstract][Full Text] [Related]
28. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
[TBL] [Abstract][Full Text] [Related]
29. Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society.
Ahn SH; Kim HJ; Lee JW; Gong GY; Noh DY; Yang JH; Jung SS; Park HY
Breast Cancer Res Treat; 2011 Nov; 130(2):507-15. PubMed ID: 21858659
[TBL] [Abstract][Full Text] [Related]
30. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1.
Qian B; Katsaros D; Lu L; Preti M; Durando A; Arisio R; Mu L; Yu H
Breast Cancer Res Treat; 2009 Sep; 117(1):131-40. PubMed ID: 18932017
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
Schmidt MK; Tollenaar RA; de Kemp SR; Broeks A; Cornelisse CJ; Smit VT; Peterse JL; van Leeuwen FE; Van't Veer LJ
J Clin Oncol; 2007 Jan; 25(1):64-9. PubMed ID: 17132695
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
[TBL] [Abstract][Full Text] [Related]
33. The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients.
Huzarski T; Byrski T; Gronwald J; Cybulski C; Oszurek O; Szwiec M; Gugała K; Stawicka M; Morawiec Z; Mierzwa T; Falco M; Janiszewska H; Kilar E; Marczyk E; Kozak-Klonowska B; Siołek M; Surdyka D; Wiśniowski R; Posmyk M; Domagała P; Sun P; Lubiński J; Narod SA;
Breast Cancer Res Treat; 2016 Apr; 156(2):371-8. PubMed ID: 26983446
[TBL] [Abstract][Full Text] [Related]
34. NBS1 8360G > C polymorphism is associated with breast cancer risk: a meta-analysis.
Wang Z; Cui D; Lu W
Breast Cancer Res Treat; 2010 Sep; 123(2):557-61. PubMed ID: 20143155
[TBL] [Abstract][Full Text] [Related]
35. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
36. Association of ionizing radiation-induced foci of NBS1 with chromosomal instability and breast cancer susceptibility.
Someya M; Sakata K; Tauchi H; Matsumoto Y; Nakamura A; Komatsu K; Hareyama M
Radiat Res; 2006 Oct; 166(4):575-82. PubMed ID: 17007554
[TBL] [Abstract][Full Text] [Related]
37. Micrometastatic node-positive breast cancer: long-term outcomes and identification of high-risk subsets in a large population-based series.
Truong PT; Lesperance M; Li KH; MacFarlane R; Speers CH; Chia S
Ann Surg Oncol; 2010 Aug; 17(8):2138-46. PubMed ID: 20151215
[TBL] [Abstract][Full Text] [Related]
38. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer risk and common single nucleotide polymorphisms in homologous recombination DNA repair pathway genes XRCC2, XRCC3, NBS1 and RAD51.
Silva SN; Tomar M; Paulo C; Gomes BC; Azevedo AP; Teixeira V; Pina JE; Rueff J; Gaspar JF
Cancer Epidemiol; 2010 Feb; 34(1):85-92. PubMed ID: 20004634
[TBL] [Abstract][Full Text] [Related]
40. Body weight and risk of breast cancer in BRCA1/2 mutation carriers.
Manders P; Pijpe A; Hooning MJ; Kluijt I; Vasen HF; Hoogerbrugge N; van Asperen CJ; Meijers-Heijboer H; Ausems MG; van Os TA; Gomez-Garcia EB; Brohet RM; ; van Leeuwen FE; Rookus MA
Breast Cancer Res Treat; 2011 Feb; 126(1):193-202. PubMed ID: 20730487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
